In the last three months, 8 analysts have published ratings on Viridian Therapeutics (NASDAQ:VRDN), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 3 | 0 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.0, a high estimate of $56.00, and a low estimate of $27.00. This current average has increased by 2.66% from the previous average price target of $33.12.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds...
Login or create a forever free account to read this news
Sign up/Log in